AutoGenomics, the leader in automated multiplexed molecular testing solutions, announced that it has launched its latest high throughput instrument this week, the INFINITI® High Throughput System. Designed to provide semi-automated multiplexed DNA analysis in an open front end system, the new platform provides highly flexible and scalable throughput from 96 to 3,456 samples tested in just 1 shift. The launch of this instrument is meant to meet the needs of high volume clinical laboratories, which now place a higher emphasis on throughput and scalability than just specialization alone.
The HTS would empower high volume clinical laboratories to perform a large menu of cost-effective and easy to use tests with a high degree of efficiency.
“The HTS allows us to meet the growing emphasis that modern molecular laboratories are placing on throughput and flexibility”, said Jim Canfield, the Vice President of Sales and Marketing at AutoGenomics. “This new platform positions AutoGenomics to be the solution of choice for this new generation of power users.”
The new system is compatible with the existing menu of more than 50 INFINITI® applications.
AutoGenomics Inc. (autogenomics.com), a privately held company based in Vista, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of personalized medicine.